Phase 2 Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People whose breast cancer has come back, where the returned cancer has been confirmed by a tissue sample (biopsy) as one of several specific types, including ductal carcinoma in-situ (DCIS) or certain types of invasive breast cancer, and where at least 3 years have passed since the end of their last course of whole-breast radiation treatment.
- People whose returned cancer (lesion) measures less than 3 cm and was treated with surgery that removed only part of the breast (partial mastectomy).
- People whose surgical margins are clear, meaning no cancer cells were found at the edges of the removed tissue, or who had a successful repeat surgery to achieve clear margins.
- People with invasive (spreading) cancer whose scans — either a CT scan of the chest and abdomen plus a bone scan, or a PET scan — show no signs the cancer has spread elsewhere in the body.
- People who are receiving or planning to receive hormone therapy or chemotherapy alongside the trial treatment, provided chemotherapy is given at least 2 weeks apart from radiation (HER2-targeted therapy may be given at the same time as radiation).
- People aged 18 or older.
- People who are able to understand the study information and are willing to sign a consent form.
- People who are reasonably well and able to carry out daily activities, based on a standard health performance scale (ECOG score of 2 or below).
- People who, in their doctor's assessment, have a life expectancy of at least 12 months.
- People of any gender identity, as this trial is open to all genders.
Who may not be able to join:
- People whose cancer has spread to lymph nodes or other parts of the body, and who are fewer than 3 years out from their previous radiation treatment.
- People whose cancer is a specific type called pure invasive lobular carcinoma, extensive lobular carcinoma in-situ, extensive DCIS spanning more than 3 cm, or a rare non-epithelial breast cancer such as lymphoma or sarcoma.
- People who have cancer in more than one area of the breast (multicentric carcinoma), or who have suspicious lymph nodes in certain areas that have not been confirmed as cancer-free by biopsy or cell testing.
- People with Paget's disease of the nipple (a rare form of breast cancer affecting the nipple area).
- People whose cancer involves the skin of the breast.
- People who have a connective tissue condition called scleroderma or dermatomyositis.
- People with psychiatric, neurological, or addiction-related conditions that would make it difficult to understand and provide informed consent.
- People who are pregnant or currently breastfeeding, due to the potential risks of radiation exposure.
- People who have a known BRCA1 or BRCA2 gene mutation.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Janice Lyons, MD, University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Phone: (216) 844-2514
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Treatment-related adverse events as graded by CTCAE criteria
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.